Literature DB >> 7979299

Decreased counts of blood neutrophils, monocytes, and platelets in human immunodeficiency virus-infected children and young adults treated with diethyldithiocarbamate.

J L Shenep1, W T Hughes, P M Flynn, P K Roberson, F G Behm, G H Fullen, S G Kovnar, K P Guito, T O Brodkey.   

Abstract

Nineteen young human immunodeficiency virus-infected patients were randomized to receive 400 mg of oral diethyldithiocarbamate (DTC) per m2 or placebo weekly for 12 weeks. Changes in blood CD4+ lymphocytes were not significantly different between groups. However, neutrophil, monocyte, and platelet counts consistently decreased during DTC treatment, suggesting DTC-mediated myelosuppression.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7979299      PMCID： PMC284606          DOI： 10.1128/AAC.38.7.1644

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  [Protection against acute copper poisoning using chelating substances].

Authors:  L BIZZI; S GARATTINI; C MOR
Journal:  Boll Soc Ital Biol Sper       Date:  1955 Jul-Aug

2.  Biphasic toxicity of diethyldithiocarbamate, a metal chelation, to T lymphocytes and polymorphonuclear granulocytes: reversal by zinc and copper.

Authors:  D A Rigas; C Eginitis-Rigas; C Head
Journal:  Biochem Biophys Res Commun       Date:  1979-05-28       Impact factor: 3.575

3.  Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection.

Authors:  J M Lang; J L Touraine; C Trepo; P Choutet; M Kirstetter; A Falkenrodt; L Herviou; J M Livrozet; G Retornaz; F Touraine
Journal:  Lancet       Date:  1988-09-24       Impact factor: 79.321

4.  Clinical characterization of imuthiol.

Authors:  E Lemarie; M Musset; C Charbonnier; M Renoux; G Renoux
Journal:  Methods Find Exp Clin Pharmacol       Date:  1986-01

5.  Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study.

Authors:  E M Hersh; G Brewton; D Abrams; J Bartlett; J Galpin; P Gill; R Gorter; M Gottlieb; J J Jonikas; S Landesman
Journal:  JAMA       Date:  1991-03-27       Impact factor: 56.272

6.  The effects of the protracted administration of the chelating agent, sodium diethyldithiocarbamate (dithiocarb).

Authors:  F W Sunderman; O E Paynter; R B George
Journal:  Am J Med Sci       Date:  1967-07       Impact factor: 2.378

7.  The influence of diethyl-dithiocarbamate ('Imuthiol') on mononuclear cells in vitro.

Authors:  C F Corke
Journal:  Int J Immunopharmacol       Date:  1984

8.  Effective therapy of the LP-BM5 murine retrovirus-induced lymphoproliferative immunodeficiency disease with diethyldithiocarbamate.

Authors:  E M Hersh; C Y Funk; K L Ryschon; E A Petersen; D E Mosier
Journal:  AIDS Res Hum Retroviruses       Date:  1991-06       Impact factor: 2.205

9.  Inhibition of HIV progression by dithiocarb. German DTC Study Group.

Authors:  E C Reisinger; P Kern; M Ernst; P Bock; H D Flad; M Dietrich
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321
  9 in total
  1 in total

1.  Dithiocarbamates and viral IL-10 collaborate in the immortalization and evasion of immune response in EBV-infected human B lymphocytes.

Authors:  Richard D Irons; Anh Tuan Le
Journal:  Chem Biol Interact       Date:  2007-11-22       Impact factor: 5.192
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.